The involvement of transforming growth factor-β1 secretion in Urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts

Regulatory Peptides

Volumn 140, Issue 1-2, 2007, Pages 88-93

  Dai, Hong Yan ^a,b   Kang, Wei Qiang ^b   Wang, Xu ^b   Yu, Xiao Jing ^c   Li, Zhen Hua ^a   Tang, Meng Xiong ^a   Xu, Dong Ling ^a   Li, Chen Wen ^a   Zhang, Yun ^a   Ge, Zhi Ming ^a  

^a Qilu Hospital of Shandong University   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Collagen; Fibroblasts; Remodeling; Transforming growth factor 1; Urotensin II

Indexed keywords

BETA ACTIN; COLLAGEN; COLLAGEN TYPE 3; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; URANTIDE; UROTENSIN; UROTENSIN II; UROTENSIN II RECEPTOR; UROTENSIN RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG POTENCY; FIBROBLAST; HEART; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; VASOCONSTRICTION;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; COLLAGEN; FIBROBLASTS; GENE EXPRESSION; MYOCARDIUM; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; UROTENSINS;

MAMMALIA; RATTUS NORVEGICUS;

EID: 33847309050     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.11.015     Document Type: Article

References (29)

1. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., Louden C.S., Foley J.J., Sauermelch C.F., Coatney R.W., Ao Z., Disa J., Holmes S.D., Stadel J.M., Martin J.D., Liu W.S., Glover G.I., Wilson S., McNulty D.E., Ellis C.E., et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
2. Bohm F., and Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 135 (2002) 25-27
3. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., Ohlstein E.H., and Willette R.N. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 (2000) 1262-1274
4. Russell F.D., Molenaar P., and O'Brien D.M. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132 (2001) 5-9
5. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jaekel K., Scheffold T., Krakau I., Schramm M., Guelker H., and Stasch J.P. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94 (2004) 93-97
6. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urotensin in human systolic heart failure. Circulation 106 (2002) 2877-2880
7. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
8. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., and Molenaar P. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285 (2003) H1576-H1581
9. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
10. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., Kelly D.J., Gilbert R.E., and Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 (2003) 246-253
11. Zhang Y., Li J., Cao J., Chen J., Yang J., Zhang Z., Du J., and Tang C. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels 16 (2002) 64-68
12. Bousette N., Hu F., Ohlstein E.H., Dhanak D., Douglas S.A., and Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 41 (2006) 285-295
13. Johns D.G., Ao Z., Naselsky D., Herold C.L., Maniscalco K., Sarov-Blat L., Steplewski K., Aiyar N., and Douglas S.A. Urotensin II-mediated cardiomyocytes hypertrophy: effect of receptor antagonist and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 238-250
14. Onan D., Pipolo L., Yang E., Hannan R.D., and Thomas W.G. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 18 (2004) 2344-2354
15. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium: fibrosis and the renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
16. Border W.A., and Nobel N.A. Transforming growth factor-β in tissue fibrosis. N Engl J Med 331 (1994) 1286-1292
17. Hein S., Arnon E., Kostin S., Schonburg M., Elsasser A., Polyakova V., Bauer E.P., Klovekorn W.P., and Schaper J. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart. Structural deterioration and compensatory mechanisms. Circulation 107 (2003) 984-991
18. Pauschinger M., Knopf D., Petschauer S., Doerner A., Poller W., Schwimmbeck P.L., Kuhl U., and Schultheiss H.P. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 99 (1999) 2750-2756
19. Li G., Li R.K., Mickle D.A., Weisel R.D., Merante F., Ball W.T., Christakis G.T., Cusimano R.J., and Williams W.G. Elevated insulin-like growth factor-I and transforming growth factor-beta 1 and their receptors in patients with idiopathic hypertrophic cardiomyopathy: a possible mechanism. Circulation 98 Suppl. 19 (1998) II-144-II-149
20. Heimer R., Bashey R.I., Kyle J., and Jiminez S.A. TGF-beta modulates the synthesis of proteoglycans by myocardial fibroblasts in culture. J Mol Cell Cardiol 27 (1995) 2191-2198
21. Eghbali M., Tomek R., Sukhatme V.P., Woods C., and Bhambi B. Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts: regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 69 (1991) 483-490
22. Kuwahara F., Kai H., Tokuda K., Kai M., Takeshita A., Egashira K., and Imaizumi T. Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106 (2002) 130-135
23. Lee A.A., Dillmann W.H., McCulloch A.D., and Villareal F.J. Angiotensin II stimulates the autocrine production of transforming growth factor-beta1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 27 (1995) 2347-2357
24. Vesey D.A., Cheung C., Cuttle L., Endre Z., Gobe G., and Johnson D.W. Interleukin-1β stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor-β-dependent mechanism. J Lab Clin Med 140 (2002) 342-350
25. Bhambi B., and Eghbali M. Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol 139 (1991) 1131-1142
26. Omura T., Kim S., Takeuchi K., Iwao H., and Takeda T. Transforming growth factor-β1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system. Cardiovasc Res 28 (1994) 1835-1842
27. Tomita H., Egashira K., Ohara Y., Takemoto M., Koyanagi M., Katoh, Yamamoto H., Tamaki K., Shimokawa H., and Takeshita A. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32 (1998) 273-279
28. Roberts A.B., and Sporn M.B. The transforming growth factor-β s. In: Sporn M.B., and Roberts A.B. (Eds). Peptide Growth Factors and Their Receptors. Handbook of Experimental Pharmacology (1990), Springer-Verlag, Heidelberg, Germany 419-472
29. Weber H., Taylor D.S., and Molloy C.J. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. J Clin Invest 93 (1994) 788-798